Document is current
Any future updates will be listed below
-
Authors
Inoue, Yoshitaka https://orcid.org/0000-0002-3967-7356
Nakano, Nobuaki https://orcid.org/0000-0001-9826-7616
Fuji, Shigeo https://orcid.org/0000-0001-5118-7950
Eto, Tetsuya
Kawakita, Toshiro
Suehiro, Youko
Miyamoto, Toshihiro https://orcid.org/0000-0002-6533-1594
Sawayama, Yasushi
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Kondo, Tadakazu https://orcid.org/0000-0002-8959-6271
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Fukuda, Takahiro
Yoshimitsu, Makoto
Kato, Koji
,
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (19K17861)
Japan Agency for Medical Research and Development (20ck0106616h0001)
- License Information
-
More Information
Article History
Received: 19 May 2021
Revised: 2 August 2021
Accepted: 19 August 2021
First Online: 31 August 2021
Competing interests
: NN: honoraria (e.g., lecture fees) from Otsuka Pharmaceutical. SF: honoraria from Kyowa Kirin. NU: honoraria from Otsuka Pharmaceutical. TK: honoraria from Otsuka Pharmaceutical. JK: honoraria from Sanofi and Otsuka Pharmaceutical. KK: consulting fees from AbbVie, AstraZeneca, Celgene, Chugai, Eisai, Janssen, Novartis, and Daiichi Sankyo; honoraria from Takeda, MSD, Kyowa-Kirin, Janssen, Celgene, Ono, Mundi, Dainippon-Sumitomo, and Bristol-Myers Squibb; research funding from Chugai, Takeda, Kyowa Kirin, AbbVie, Novartis, Eisai, Janssen, Celgene, Ono, Novartis, and Daiichi Sankyo. The other authors declare no conflicts of interest associated with this manuscript.
